MedTrace Logo

The Effect of E-EPA on Circulating LDL and Plasma Lipid Metabolism

NCT04152291 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2025-09-22

Study results available
· View outcomes & findings →

Summary

40-70 healthy volunteers of ages 18 to 65 participate in a E-EPA-diet where 3,9 grams of E-EPA is added to their normal diet and lifestyles for a month. Blood samples will be collected before the study and at weeks 1 and 4 and also, two weeks after finishing the diet. Main study focuses are LDL aggregation susceptibility, lipid composition and proteoglycan binding affinity. In addition, important plasma lipid metabolism enzymes and lipid mediated resolvins are measured as well as several baseline characteristics.

Conditions

Interventions

DIETARY_SUPPLEMENT

Ethyl-Eicosapentaenoic Acid (E-EPA)

3,9 grams of E-EPA (Icosapent ethyl) is added to participants' normal diet.

Sponsors & Collaborators

  • University of Helsinki

    collaborator OTHER

  • Wihuri Research Institute

    lead OTHER

Principal Investigators

  • Katariina Öörni, Professor, Ph.D · Wihuri Research Institute

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-11-12
Primary Completion
2024-06-30
Completion
2024-12-31

Countries

  • Finland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04152291 on ClinicalTrials.gov